Argent BioPharma (ASX:RGT) has completed the acquisition of AusCann Group Holdings' interest in CannPal Animal Therapeutics, marking an important step in strengthening its neurological pipeline and expanding its reach into veterinary medicine.
The transaction, approved by shareholders at a recent general meeting, also includes an option to acquire the Neuvis drug delivery platform, adding further technical depth and future flexibility to the company’s development strategy.
CannPal brings with it a late-stage veterinary pharmaceutical program focused on epilepsy in companion animals, particularly targeting seizure management in dogs.
Having progressed to Phase 3, the program offers a defined regulatory pathway and positions Argent BioPharma for potential near-term commercialisation. The clinical and safety dataset generated by CannPal also provides a translational foundation that supports the company’s broader neurological ambitions, especially in relation to its lead human asset, CannEpil.
By integrating CannPal’s advanced clinical and regulatory data, the company strengthens the overall evidentiary base underpinning its seizure-related therapies. At the same time, the optionality tied to the Neuvis platform can help improve formulation performance, bioavailability, and product lifecycles across multiple assets.
Neuvis is a proprietary oral drug delivery system designed to optimise the absorption and utilisation of therapies within the body. Its potential application across Argent BioPharma’s pipeline could improve products and strengthen intellectual property, reinforcing the company’s long-term competitiveness in both human and veterinary markets.
Managing Director and CEO Roby Zomer framed the acquisition as a coherent extension of the company’s existing strategy, stating, “The completion of the CannPal acquisition represents a strategically aligned step in strengthening Argent BioPharma’s neurological portfolio. By adding a late-stage epilepsy programme with standalone commercial potential, while enhancing the data and positioning around CannEpil, we are reinforcing both the depth and coherence of our asset base. The inclusion of the Neuvis option further adds platform-level optionality as we continue to build a scalable and IP-driven pipeline aligned with our US growth strategy.”